Streetbeat News

NVAX

Novavax, Inc.

https://www.novavax.com

Industry

Biotechnology

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Open

7.14

Mkt cap

1.2B

Volume

High

7.33

P/E Ratio

-3.01

52-wk high

23.86

Low

6.81

Div yield

N/A

52-wk low

3.53

Novavax announced a global restructuring and cost reduction plan in May 2023, which includes a 30% reduction in workforce by the end of 1Q'23. Additionally, in January 2024, the company plans to reduce its global workforce by an additional 12%, including a 9% reduction in full-time employees and the remainder in contractors and consultants.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:44 pm

The article lists companies scheduled to report their earnings on February 28, 2024, including their expected earnings per share and revenue. It covers a wide range of sectors and provides a comprehensive overview of the financial performance expectations for these companies.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 11:24 am

Beyond Meat, Viking Therapeutics, Novavax, Baidu, and Tesla were among the top stocks on investors' radars, with varied performances. Beyond Meat reported Q4 revenues beating estimates, Viking Therapeutics surged after promising Phase 2 data, Novavax is awaited for its quarterly earnings, Baidu is expected to report positive EPS, and Tesla saw a modest increase amid speculation and comments from Jim Cramer.

Portfolio Pulse from Benzinga Neuro

February 28, 2024 | 2:06 am

Novavax (NASDAQ:NVAX) is scheduled to release its quarterly earnings report on February 28, 2024, with analysts expecting an EPS of $-0.50. Despite past earnings beats, Novavax's stock price has experienced declines following earnings announcements. Shares are currently trading at $5.5, down 16.18% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

Etsy shares fell by around 8% after reporting mixed Q4 financial results, missing earnings estimates but beating sales forecasts. Other stocks showed significant movements, with La Rosa Holdings, BuzzFeed, and Monopar Therapeutics among the top gainers, while Draganfly, Greenbrook TMS, and Synaptogenix led the losers. Notable movements were also seen in companies like Rivian Automotive, Lucid Group, and Sunnova Energy due to various announcements and financial results.

Portfolio Pulse from Avi Kapoor

February 22, 2024 | 6:38 pm

Health care stocks experienced significant movements in Thursday's intraday session. Monopar Therapeutics and Calidi Biotherapeutics led the gainers with over 75% increases in their stock prices, while Synaptogenix and Motus GI Holdings were among the top losers, with over 20% declines. Notably, Amylyx Pharma and SenesTech released their Q4 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:31 pm

NICE Ltd. reported better-than-expected Q4 financial results, leading to a 10.4% stock increase. Other companies like Root, Inc., Novavax, Inc., and NVIDIA Corporation also saw significant gains following positive financial results or settlements. The overall market sentiment was positive, with the Nasdaq Composite gaining more than 2%.

Portfolio Pulse from Avi Kapoor

February 22, 2024 | 4:33 pm

Novavax Inc (NASDAQ:NVAX) shares are trading higher after reaching a settlement with Gavi for its 2021 vaccine advance purchase agreement. The settlement closes pending arbitration and involves an initial payment of $75 million by Novavax, with deferred payments of $80 million annually through 2028 and an additional vaccine credit of up to $225 million. Novavax is expected to report a Q4 loss of 50 cents per share and revenue of $321.66 million. The company does not pay dividends but engages in other capital allocation programs.

Portfolio Pulse from Adam Eckert

February 22, 2024 | 3:28 pm

Novavax shares are trading higher following the announcement of a settlement with Gavi for its 2021 vaccine advance purchase agreement. This development could potentially impact investor sentiment and the stock's short-term performance.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 3:28 pm

Novavax has settled with Gavi over the 2021 Advance Purchase Agreement for its Covid-19 vaccine, NVX-COV2373. The settlement includes an initial payment of $75 million, deferred payments totaling $400 million through 2028, and up to $225 million in additional vaccine credits for low-income countries. This agreement emphasizes both parties' commitment to public health and equitable vaccine distribution.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 11:06 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.